Company: Movetis
Financing: $63.5M

Belgium-based Movetis was founded in 2006 after the company acquired a portfolio of gastrointestinal candidates from Johnson & Johnson subsidiaries Janssen and Ortho-McNeil. In January, the company landed a €49 million ($63.5M) first round led by Sofinnova Partners and Life Sciences Partners. Sofinnova Ventures, KBC, GIMV, Quest for Growth and BIP Investment Partners also participated.

The company’s lead candidate is RESOLOR, which is in Phase III development for the treatment of severe chronic constipation and is expected to his the market by 2009. A second compound, M0002, is in Phase IIa development for treatment of ascites. Movetis has two other clinical-stage candidates: one for pediatric reflux and a second for diabetic gastroparesis.



Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.